Pradaxa and Xarelto: A Case Study in Evidence Based Medicine

Описание: A discussion of the controversies surrounding the RE-LY and ROCKET-AF trials, which led to the initial FDA approvals of dabigatran (Pradaxa) and rivaroxaban (Xarelto) respectively.

Please note that in the years since this video was posted, additional studies have been published which support the use of these drugs. I leave the video up because the issues discussed are still relevant. However, if you are a layperson, please do NOT stop taking your Xarelto or Pradaxa just because you watched this video. Instead, discuss your concerns with your physician. There are more than one alternative anticoagulant out there.

I declare that I have no conflicts of interest, and receive no compensation from the pharmaceutical or device industries.

Original RE-LY Trial: http://www.ncbi.nlm.nih.gov/pubmed/19...

Original ROCKET-AF Trial: http://www.ncbi.nlm.nih.gov/pubmed/21...

BMJ Criticisms of Dabigatran RE-LY:
http://www.ncbi.nlm.nih.gov/pubmed/25...
http://www.ncbi.nlm.nih.gov/pubmed/25...
http://www.ncbi.nlm.nih.gov/pubmed/25...

BMJ Criticism of ROCKET-AF and Rivaroxaban:
http://www.ncbi.nlm.nih.gov/pubmed/26...


Recent media coverage of dabigatran and RE-LY:
https://www.washingtonpost.com/news/f...
http://www.nytimes.com/2014/02/08/bus...
http://www.nytimes.com/2014/02/06/bus...

Recent media coverage of rivaroxaban and ROCKET-AF:
http://www.nytimes.com/2016/02/23/bus...
http://www.cbsnews.com/news/did-heart...